Published in Ann Neurol on September 01, 2003
Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci U S A (2007) 2.03
Cytokine and chemokine regulation of sensory neuron function. Handb Exp Pharmacol (2009) 1.70
Chemokines: integrators of pain and inflammation. Nat Rev Drug Discov (2005) 1.68
CXCR4 chemokine receptor signaling mediates pain hypersensitivity in association with antiretroviral toxic neuropathy. Brain Behav Immun (2007) 1.53
Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain. Brain (2007) 1.25
Increased chemokine signaling in a model of HIV1-associated peripheral neuropathy. Mol Pain (2009) 1.22
Dorsal Root Ganglia Sensory Neuronal Cultures: a tool for drug discovery for peripheral neuropathies. Expert Opin Drug Discov (2009) 1.21
Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy. Pain (2007) 1.21
Glial TNFα in the spinal cord regulates neuropathic pain induced by HIV gp120 application in rats. Mol Pain (2011) 1.15
Comparison of dorsal root ganglion gene expression in rat models of traumatic and HIV-associated neuropathic pain. Eur J Pain (2008) 1.12
Autonomic dysfunction is common in HIV and associated with distal symmetric polyneuropathy. J Neurovirol (2013) 1.10
Animal models of peripheral neuropathies. Neurotherapeutics (2012) 1.09
Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine (2012) 1.03
Mechanisms of distal axonal degeneration in peripheral neuropathies. Neurosci Lett (2015) 1.00
Neuromuscular diseases associated with HIV-1 infection. Muscle Nerve (2009) 0.99
Differential effects of HIV infected macrophages on dorsal root ganglia neurons and axons. Exp Neurol (2007) 0.97
Macrophage-mediated dorsal root ganglion damage precedes altered nerve conduction in SIV-infected macaques. Am J Pathol (2011) 0.97
HIV-related neuropathy: current perspectives. HIV AIDS (Auckl) (2013) 0.93
Schwann cells as a therapeutic target for peripheral neuropathies. CNS Neurol Disord Drug Targets (2010) 0.92
HIV-1, chemokines and neurogenesis. Neurotox Res (2005) 0.91
Altered cutaneous nerve regeneration in a simian immunodeficiency virus / macaque intracutaneous axotomy model. J Comp Neurol (2009) 0.90
Murine immunodeficiency virus-induced peripheral neuropathy and the associated cytokine responses. J Immunol (2012) 0.90
Nitric oxide prevents axonal degeneration by inducing HIF-1-dependent expression of erythropoietin. Proc Natl Acad Sci U S A (2011) 0.86
Direct effects of HIV-1 Tat on excitability and survival of primary dorsal root ganglion neurons: possible contribution to HIV-1-associated pain. PLoS One (2011) 0.83
SIV-induced impairment of neurovascular repair: a potential role for VEGF. J Neurovirol (2012) 0.83
Selected statins produce rapid spinal motor neuron loss in vitro. BMC Musculoskelet Disord (2012) 0.81
The Molecular and Pharmacological Mechanisms of HIV-Related Neuropathic Pain. Curr Neuropharmacol (2013) 0.81
Spinal NF-κB and chemokine ligand 5 expression during spinal glial cell activation in a neuropathic pain model. PLoS One (2015) 0.80
TNFα is involved in neuropathic pain induced by nucleoside reverse transcriptase inhibitor in rats. Brain Behav Immun (2011) 0.80
Interleukin-4 regulates the expression of CD209 and subsequent uptake of Mycobacterium leprae by Schwann cells in human leprosy. Infect Immun (2010) 0.80
Persistent Peripheral Nervous System Damage in Simian Immunodeficiency Virus-Infected Macaques Receiving Antiretroviral Therapy. J Neuropathol Exp Neurol (2015) 0.80
Gp120 in the pathogenesis of human immunodeficiency virus-associated pain. Ann Neurol (2014) 0.79
GPI-1046 protects dorsal root ganglia from gp120-induced axonal injury by modulating store-operated calcium entry. J Peripher Nerv Syst (2009) 0.79
Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. Pharmacogenomics (2009) 0.78
Interleukin 10 mediated by herpes simplex virus vectors suppresses neuropathic pain induced by human immunodeficiency virus gp120 in rats. Anesth Analg (2014) 0.78
IL-10 mediated by herpes simplex virus vector reduces neuropathic pain induced by HIV gp120 combined with ddC in rats. Mol Pain (2014) 0.78
Microvesicles shed from microglia activated by the P2X7-p38 pathway are involved in neuropathic pain induced by spinal nerve ligation in rats. Purinergic Signal (2016) 0.78
Macrophage-sensory neuronal interaction in HIV-1 gp120-induced neurotoxicity‡. Br J Anaesth (2014) 0.78
Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy. Neuropharmacology (2014) 0.77
Loss of intraepidermal nerve fiber density during SIV peripheral neuropathy is mediated by monocyte activation and elevated monocyte chemotactic proteins. J Neuroinflammation (2015) 0.77
Animal models of HIV peripheral neuropathy. Future Virol (2014) 0.77
Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211. HIV Clin Trials (2010) 0.76
HIV Glycoprotein Gp120 Impairs Fast Axonal Transport by Activating Tak1 Signaling Pathways. ASN Neuro (2016) 0.75
Antinociceptive effects of topical mepivacaine in a rat model of HIV-associated peripheral neuropathic pain. J Pain Res (2016) 0.75
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol (2005) 5.95
The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS (2007) 5.18
The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (2005) 4.48
HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol (2002) 4.20
DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet (2004) 3.72
Differences between human and mouse embryonic stem cells. Dev Biol (2004) 3.30
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol (2010) 2.91
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
A hierarchical NGF signaling cascade controls Ret-dependent and Ret-independent events during development of nonpeptidergic DRG neurons. Neuron (2007) 2.83
Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J Neurosci (2009) 2.71
Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology (2012) 2.30
Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry (2010) 2.30
Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol (2006) 2.27
A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis (2005) 2.25
Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol (2009) 2.14
A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med (2009) 1.96
An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol (2007) 1.94
High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol (2013) 1.90
The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain (2004) 1.90
Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol (2004) 1.87
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther (2012) 1.79
Diffusion tensor magnetic resonance imaging of Wallerian degeneration in rat spinal cord after dorsal root axotomy. J Neurosci (2009) 1.79
The effect of the alignment of electrospun fibrous scaffolds on Schwann cell maturation. Biomaterials (2007) 1.72
Recovery from paralysis in adult rats using embryonic stem cells. Ann Neurol (2006) 1.69
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A (2005) 1.69
Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS (2002) 1.68
Diabetes and driving. Diabetes Care (2012) 1.66
HIV-associated sensory neuropathies. AIDS (2002) 1.65
Evaluating sleep and cognition in HIV. J Acquir Immune Defic Syndr (2013) 1.64
Neuroimmunophilin ligands protect cavernous nerves after crush injury in the rat: new experimental paradigms. Eur Urol (2006) 1.63
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology (2013) 1.62
Hashimoto's encephalopathy. Ann N Y Acad Sci (2008) 1.57
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol (2011) 1.57
Clinical validation of the NeuroScreen. J Neurovirol (2005) 1.57
Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read (2002) 1.56
HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS (2010) 1.56
Peripheral neuropathy in HIV: prevalence and risk factors. AIDS (2011) 1.53
Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology (2004) 1.49
Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol (2006) 1.49
Diagnostic utility of the subjective peripheral neuropathy screen in HIV-infected persons with peripheral sensory polyneuropathy. AIDS Read (2005) 1.46
Low atazanavir concentrations in cerebrospinal fluid. AIDS (2009) 1.45
Motor neuron disease occurring in a mutant dynactin mouse model is characterized by defects in vesicular trafficking. J Neurosci (2008) 1.45
Improving neurological outcomes post-cardiac arrest in a rat model: immediate hypothermia and quantitative EEG monitoring. Resuscitation (2007) 1.44
Aligned Protein-Polymer Composite Fibers Enhance Nerve Regeneration: A Potential Tissue-Engineering Platform. Adv Funct Mater (2007) 1.43
Quantitative MR spectroscopic imaging of brain lesions in patients with AIDS: correlation with [11C-methyl]thymidine PET and thallium-201 SPECT. Acad Radiol (2002) 1.43
Growth Hormone Therapy Accelerates Axonal Regeneration, Promotes Motor Reinnervation, and Reduces Muscle Atrophy following Peripheral Nerve Injury. Plast Reconstr Surg (2016) 1.43
Loss of ALS2 function is insufficient to trigger motor neuron degeneration in knock-out mice but predisposes neurons to oxidative stress. J Neurosci (2005) 1.43
Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J Virol (2008) 1.40
Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology (2005) 1.39
Glial cell line-derived neurotrophic factor alters axon schwann cell units and promotes myelination in unmyelinated nerve fibers. J Neurosci (2003) 1.38
Diagnosis and management of acute myelopathies. Neurologist (2005) 1.38
Degeneration of myelinated efferent fibers induces spontaneous activity in uninjured C-fiber afferents. J Neurosci (2002) 1.36
Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol (2006) 1.33
Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr (2005) 1.32
Myelin-associated glycoprotein and complementary axonal ligands, gangliosides, mediate axon stability in the CNS and PNS: neuropathology and behavioral deficits in single- and double-null mice. Exp Neurol (2005) 1.32
Axonal protective effects of the myelin-associated glycoprotein. J Neurosci (2009) 1.29
A novel endogenous erythropoietin mediated pathway prevents axonal degeneration. Ann Neurol (2004) 1.28
Diabetes and employment. Diabetes Care (2013) 1.28
Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS. J Neurovirol (2005) 1.23
The Ste20 kinases Ste20-related proline-alanine-rich kinase and oxidative-stress response 1 regulate NKCC1 function in sensory neurons. J Biol Chem (2009) 1.23
Transverse Myelitis: pathogenesis, diagnosis and treatment. Front Biosci (2004) 1.23
HIV-associated opportunistic infections of the CNS. Lancet Neurol (2012) 1.22
Denervation of skin in neuropathies: the sequence of axonal and Schwann cell changes in skin biopsies. Brain (2007) 1.21
Increased fibronectin expression in sturge-weber syndrome fibroblasts and brain tissue. Pediatr Res (2003) 1.21
Sleep, function and HIV: a multi-method assessment. AIDS Behav (2013) 1.20
beta1-integrin mediates myelin-associated glycoprotein signaling in neuronal growth cones. Mol Brain (2008) 1.19
Recent advances in HIV neuropathy. Curr Opin Neurol (2006) 1.17
Assessment of epidermal nerve fibers: a new diagnostic and predictive tool for peripheral neuropathies. J Neuropathol Exp Neurol (2007) 1.15
In vitro modeling of the HIV-macrophage reservoir. J Leukoc Biol (2006) 1.13
Transplanted neural stem cells promote axonal regeneration through chronically denervated peripheral nerves. Exp Neurol (2004) 1.13
Saving the clinician-scientist: report of the ANA long range planning committee. Ann Neurol (2006) 1.12
Hydroxychloroquine causes severe vacuolar myopathy in a patient with chronic graft-versus-host disease. Am J Hematol (2005) 1.12
Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy. J Neuroimmunol (2011) 1.12
Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann Neurol (2002) 1.11
Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol (2003) 1.11
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol (2008) 1.10
IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest (2005) 1.10
Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol (2009) 1.09
Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr (2002) 1.09
Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain (2002) 1.08
Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol (2008) 1.08
Epidermal reinnervation after intracutaneous axotomy in man. J Comp Neurol (2003) 1.08
Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. J Acquir Immune Defic Syndr (2006) 1.08
Depressive symptoms, quality of life, and neuropsychological performance in HIV/AIDS: the impact of gender and injection drug use. J Neurovirol (2005) 1.08
Peripheral nerve-derived HIV-1 is predominantly CCR5-dependent and causes neuronal degeneration and neuroinflammation. Virology (2005) 1.07